key: cord-0830231-x7rlek05
authors: Xuan, Wei; Chen, Caiyang; Jiang, Xuliang; Zhang, Xiao; Zhu, Hui; Zhang, Song; Yu, Weifeng; Peng, Zhiyong; Su, Diansan
title: Clinical characteristics and outcomes of five critical COVID-19 patients treated with extracorporeal membrane oxygenation in Leishenshan Hospital in Wuhan
date: 2020-08-31
journal: J Clin Anesth
DOI: 10.1016/j.jclinane.2020.110033
sha: f6a089074285c057bcbb22e90553f642d8b79999
doc_id: 830231
cord_uid: x7rlek05

• Providing early ECMO support due to carbon dioxide retention and on-time decannulation may be more beneficial to patients. • The duration from tracheal intubation to ECMO cannulation was more than 7 days in some patients. • The application rules of ECMO vary in different regions.

A letter to the editor, Extracorporeal membrane oxygenation (ECMO) is a valuable lifesaving treatment for patients with acute respiratory distress syndrome (ARDS) [1, 2] . However, information regarding the feasibility of ECMO in patients with critical COVID-19 infection is limited [3] .

In the present study, we describe the detailed clinical characteristics of five patients with critical COVID-19 infection treated with ECMO at Leishenshan Hospital, which is one of the designated hospitals to treat patients with COVID-19-related pneumonia in Wuhan, China.

Leishenshan Hospital was established in a short period of 11 days and has a capacity of 1600 beds. The hospital has two ICUs and admitted around 120 severe patients when the Shanghai medical team stationed there. We reviewed the data of five patients treated with ECMO from its opening time on February 8 to the closing time on April 15, 2020. This clinical study was approved by the Ethics Commission of Renji Hospital (Ethical Committee approval number: KY2020-34). Because of the retrospective nature of the study, informed consent was waived and approved by Ethics Commission of Renji Hospital.

All the five patients were native residents of Wuhan with an epidemiological exposure to COVID-19. Their mean age was 61.6 years (SD = 9.18). Patient 5 was successfully weaned from ECMO as expected, and Patient 4 was decannulated out of the plan due to blood infection; both patients received 1-week ECMO support and survived. The other three nonsurvivors received ECMO for a longer duration of more than 2 weeks but ultimately died.

The mean duration from the onset of symptoms to hospital admission was 6.4 days (SD = 0.49), whereas the median duration to intensive care unit (ICU) admission was 21 days (SD = 4.98). All patients experienced cough as an onset symptom, and four of them had a fever.

Regarding the other common symptoms, one patient had diarrhea, one had malaise, and none had vomiting. All patients deteriorated into dyspnea and received tracheal intubation before ECMO application. The most common chronic diseases they had were hypertension (80%) and diabetes (60%), and coronary disease and sequela stage of cerebral infarction were reported in two patients. It was noteworthy that the five patients' positive nucleic acid testing turned into negative after ICU admission, and all were positive for COVID-19 antibody after ICU treatment. Except for the patient who had been intubated already before the ICU admission, the other four patients received either high-flow nasal cannula or noninvasive ventilation treatment or both before tracheal intubation. Organ damage is a common comorbidity, and cardiac injury and liver dysfunction were observed in all patients. Patient 5 had acute kidney injury, along with three other patients, but was the only one who did not develop hyperglycemia( Table 1 ). The last laboratory data before ECMO cannulation of five patients are presented in Supplementary Table 1. Along with low oxygen index or carbon dioxide retention that necessitated ECMO support, the most abnormal data indicated that all patients suffered from infections, cardiac injury, liver dysfunction, and inflammatory responses. Patient 4 had an oxygenation index of 75 and was forced to withdraw from ECMO 1 week later due to blood infection but then survived. Patient 5 who survived received ECMO treatment due to prolonged carbon dioxide retention, which was slightly >200. The other three nonsurvivors received ECMO because of an extremely low oxygen index. The initial ECMO settings are listed in Table 1 .

The role of ECMO in managing the global COVID-19 epidemic remains unclear; especially, the criteria for patient selection and timing of ECMO initiation are yet to be clarified [1] ; hence, the application rules of ECMO vary in different regions [4] . We also applied ECMO treatment to Patient 2 who also suffered from lymphoma and the duration from tracheal intubation to ECMO cannulation was more than 7 days in Patients 2 and 5, which also did not comply with the common suggestion for ECMO use. For a flexible use, Patient 4 received ECMO to treat his hypercapnic respiratory failure, which has been reported to receive huge benefit from ECMO technique[5].

In conclusion, providing early ECMO support due to carbon dioxide retention and ontime decannulation may be more beneficial to patients. However, the effect of ECMO for end-stage patients is still limited, and preventing the progression from mild to severe case remains the most important issue. The importance of ECMO in critical COVID-19 patients warrants further studies.

ECMO use in COVID-19: lessons from past respiratory virus outbreaks-a narrative review

Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus

The Science Underlying COVID-19: Implications for the Cardiovascular System

Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience